Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.40 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809138 | 0.93 | PTPN2 (0.41) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL1843321 | 0.89 | FFAR4 (0.43) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL1809970 | 0.88 | FFAR1 (0.45) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL1812321 | 0.86 | PTPN2 (0.49) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL1816688 | 0.86 | PTGDR2 (0.44) | TP53MAPTCCR2LMNATHRB | |
| SCHEMBL3916191 | 0.85 | PTPN2 (0.43) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL3911560 | 0.84 | PTPN2 (0.45) | TP53MAPTCCR9CCR2PTPN2 | |
| SCHEMBL3907047 | 0.82 | BRAF (0.44) | — | |
| SCHEMBL3906955 | 0.81 | PTPN2 (0.43) | TP53MAPTCCR2PTPN2PTPN1 | |
| SCHEMBL1811639 | 0.81 | PTGDR2 (0.48) | TP53MAPTLMNATHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101027286-B | Indazolone derivatives as 11b-HSD1 inhibitors | HOFFMANN LA ROCHE | 2011-05-25 | — | — | CN | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| CN-101027286-A | Indazolone derivatives as 11 b-HSD 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| CN-101027286-B | Indazolone derivatives as 11b-HSD1 inhibitors | HOFFMANN LA ROCHE | 2011-05-25 | — | — | CN | disclosed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| CN-101027286-A | Indazolone derivatives as 11 b-HSD 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | TP53 4361/4885MAPT 2996/4885CCR9 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.